Sakata H, Kakehashi H, Fujita K, Yoshioka H
Department of Pediatrics, Asahikawa Medical College, Japan.
Antimicrob Agents Chemother. 1990 Jun;34(6):1045-7. doi: 10.1128/AAC.34.6.1045.
The effects of aztreonam on fecal flora and on descarboxy prothrombin (PIVKA-II) in plasma and gamma-carboxyglutamic acid (Gla) in urine as an index of vitamin K metabolism were studied in seven children (age range, 2 months to 2 years) with urinary tract infections. Daily doses of aztreonam were 60 to 80 mg/kg. Stool specimens were obtained before the treatment, on days 3 to 5 of aztreonam use, and from 3 to 5 days after the cessation of treatment. The counts of enterobacteria decreased (P less than 0.01) and those of streptococci increased (P less than 0.05) during aztreonam treatment. The anaerobic organisms, especially bifidobacteria and bacteroides, showed no marked change. PIVKA-II and Gla were investigated before and during the treatment with aztreonam. PIVKA-II was not detected in seven patients before or during aztreonam use. There were no significant differences in the levels of Gla in urine before or during the treatment.
研究了氨曲南对7名（年龄范围为2个月至2岁）患有尿路感染儿童的粪便菌群、血浆中脱羧凝血酶原（PIVKA-II）以及作为维生素K代谢指标的尿中γ-羧基谷氨酸（Gla）的影响。氨曲南的日剂量为60至80mg/kg。在治疗前、使用氨曲南的第3至5天以及治疗停止后的3至5天采集粪便标本。在氨曲南治疗期间，肠杆菌计数减少（P<0.01），链球菌计数增加（P<0.05）。厌氧生物，尤其是双歧杆菌和拟杆菌，无明显变化。在氨曲南治疗前和治疗期间对PIVKA-II和Gla进行了研究。在7名患者使用氨曲南之前或期间均未检测到PIVKA-II。治疗前或治疗期间尿中Gla水平无显著差异。
